Liversidge GG - Search Results

1

A formulation strategy for gamma secretase inhibitor ELND006, a BCS class II compound: development of a nanosuspension formulation with improved oral bioavailability and reduced food effects in dogs.

Quinn K, Gullapalli RP, Merisko-Liversidge E, Goldbach E, Wong A, Liversidge GG, Hoffman W, Sauer JM, Bullock J, Tonn G. Quinn K, et al. Among authors: liversidge gg. J Pharm Sci. 2012 Apr;101(4):1462-74. doi: 10.1002/jps.23034. Epub 2011 Dec 28. J Pharm Sci. 2012. PMID: 22213574

2

Nanosizing: a formulation approach for poorly-water-soluble compounds.

Merisko-Liversidge E, Liversidge GG, Cooper ER. Merisko-Liversidge E, et al. Among authors: liversidge gg. Eur J Pharm Sci. 2003 Feb;18(2):113-20. doi: 10.1016/s0928-0987(02)00251-8. Eur J Pharm Sci. 2003. PMID: 12594003 Review.

3

Insulin nanoparticles: a novel formulation approach for poorly water soluble Zn-insulin.

Merisko-Liversidge E, McGurk SL, Liversidge GG. Merisko-Liversidge E, et al. Among authors: liversidge gg. Pharm Res. 2004 Sep;21(9):1545-53. doi: 10.1023/b:pham.0000041446.14569.e2. Pharm Res. 2004. PMID: 15497677

4

Drug nanoparticles: formulating poorly water-soluble compounds.

Merisko-Liversidge EM, Liversidge GG. Merisko-Liversidge EM, et al. Among authors: liversidge gg. Toxicol Pathol. 2008 Jan;36(1):43-8. doi: 10.1177/0192623307310946. Toxicol Pathol. 2008. PMID: 18337220 Review.

5

Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology.

Merisko-Liversidge E, Liversidge GG. Merisko-Liversidge E, et al. Among authors: liversidge gg. Adv Drug Deliv Rev. 2011 May 30;63(6):427-40. doi: 10.1016/j.addr.2010.12.007. Epub 2011 Jan 9. Adv Drug Deliv Rev. 2011. PMID: 21223990 Review.

6

Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs.

Merisko-Liversidge E, Sarpotdar P, Bruno J, Hajj S, Wei L, Peltier N, Rake J, Shaw JM, Pugh S, Polin L, Jones J, Corbett T, Cooper E, Liversidge GG. Merisko-Liversidge E, et al. Among authors: liversidge gg. Pharm Res. 1996 Feb;13(2):272-8. doi: 10.1023/a:1016051316815. Pharm Res. 1996. PMID: 8932448

7

The electrophoretic mobility of tripeptides as a function of pH and ionic strength: comparison with iontophoretic flux data.

VanOrman Huff B, Liversidge GG, McIntire GL. VanOrman Huff B, et al. Among authors: liversidge gg. Pharm Res. 1995 May;12(5):751-5. doi: 10.1023/a:1016224028821. Pharm Res. 1995. PMID: 7479563

8

In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol.

Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T. Jinno J, et al. Among authors: liversidge gg. J Control Release. 2008 Aug 25;130(1):29-37. doi: 10.1016/j.jconrel.2008.05.013. Epub 2008 May 19. J Control Release. 2008. PMID: 18582979

9

Influence of indomethacin amphoteric gel on gastric ulcerogenicity and absorption of indomethacin in rats.

Liversidge GG, Dent J, Eickhoff WM. Liversidge GG, et al. Pharm Res. 1989 Jan;6(1):44-8. doi: 10.1023/a:1015895501832. Pharm Res. 1989. PMID: 2717517

10

Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs.

Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T. Jinno J, et al. Among authors: liversidge gg. J Control Release. 2006 Mar 10;111(1-2):56-64. doi: 10.1016/j.jconrel.2005.11.013. Epub 2006 Jan 10. J Control Release. 2006. PMID: 16410029

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

19 results

Search Page